SARS-CoV-2 main protease inhibition through dimerization promotion by peptidomimetic inhibitors and disruption by ebselen
eLife · 2026
DOI: 10.7554/elife.109956 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Chengxi Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, Food Safety and Technology Research Centre, and Research Centre for Chinese Medicine Innovation, The Hong Kong Polytechn…. Hauptthemen laut MEDLINE: Organoselenium Compounds, Peptidomimetics, Azoles, Coronavirus 3C Proteases. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, University Grants Committee.
Abstract (Originalsprache)
The SARS-CoV-2 main protease (M pro ) is a key antiviral target that equilibrates between an active dimer and inactive monomer, making the dimerization interface a promising therapeutic vulnerability. This study investigates M pro monomer-dimer equilibrium and conformational changes induced by inhibitor binding using 13 C labeling with native mass spectrometry and hydrogen/deuterium exchange mass spectrometry (HDX-MS). We evaluated how peptidomimetic inhibitors (PF-07321332, PF-00835231, GC376, boceprevir) and non-peptidomimetic inhibitors (carmofur, ebselen, MR6-31-2, AT7519, pelitinib) influence M pro dimerization and subunit exchange. Key findings revealed divergent mechanisms: peptidomimetic inhibitors significantly shifted the equilibrium towards the dimeric state, suppressing subunit exchange dynamics and rigidifying the dimer interface; in contrast, ebselen impaired dimer formation and increased interface flexibility. Notably, tandem mass spectrometry identified a novel covalent binding site for ebselen at C300. Molecular dynamics simulations and mutational analyses demonstrated that this C300 modification allosterically alters the hydrogen bond network of the dimer interface, directly contributing to ebselen-mediated dimer disruption and enzymatic inhibition. Overall, this study clarifies distinct inhibitory modes between peptidomimetics and ebselen, highlighting the therapeutic potential of targeting allosteric sites at the dimer interface for designing next-generation M pro inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences, Food Safety and Technology Research Centre, and Research Centre for Chinese Medicine Innovation, The Hong Kong Polytechnic University, Hong Kong, China.
- State Key Laboratory of Chinese Medicine and Molecular Pharmacology (Incubation), and Shenzhen Key Laboratory of Food Biological Safety Control, Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen, Ch…
ORCID-Profile: Chengxi Liu, Zhong-Ping Yao
Förderung
- National Key Research and Development Program of China
- University Grants Committee
Zitieren
APA
Liu, C., Jia, Q., Zhao, C., & Yao, Z. P. (2026). SARS-CoV-2 main protease inhibition through dimerization promotion by peptidomimetic inhibitors and disruption by ebselen. eLife. https://doi.org/10.7554/elife.109956
Vancouver
Liu C, Jia Q, Zhao C, Yao ZP. SARS-CoV-2 main protease inhibition through dimerization promotion by peptidomimetic inhibitors and disruption by ebselen. eLife. 2026. doi:10.7554/elife.109956
BibTeX
@article{Liu2026,
author = {Liu, Chengxi and Jia, Qinyu and Zhao, Chang and Yao, Zhong-Ping},
title = {SARS-CoV-2 main protease inhibition through dimerization promotion by peptidomimetic inhibitors and disruption by ebselen},
journal = {eLife},
year = {2026},
doi = {10.7554/elife.109956}
}
EUVIMED